InvestorsHub Logo
Followers 16
Posts 1609
Boards Moderated 0
Alias Born 04/20/2011

Re: lasers post# 218799

Friday, 07/29/2016 10:52:50 AM

Friday, July 29, 2016 10:52:50 AM

Post# of 400554
Best guess would be Fentanyl Buccal (generic of Orexo's Abstral) which went off patent last year. Just thinking about the fact that Actavis filed an ANDA and then Orexo filed patent infringement litigation which they settled last October. I still believe Actavis and Hakim are attached somehow and Mikah is just ingenious "non-affiliated" subsidiary. It's a sublingual tablet though so not entirely sure.

Buprenorphine could be a sleeper candidate. Is there a list available of what both companies currently have. If so, could hone in a bit more.

Do you have any thoughts?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News